183 related articles for article (PubMed ID: 23536726)
1. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
2. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.
Pozios I; Hering NA; Guenzler E; Arndt M; Elezkurtaj S; Knösel T; Bruns CJ; Margonis GA; Beyer K; Seeliger H
J Cancer Res Clin Oncol; 2023 Jan; 149(1):271-280. PubMed ID: 36495330
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
4. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
5. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer-Derived Exosomes Alter Macrophage Polarization
Ham S; Lima LG; Chai EPZ; Muller A; Lobb RJ; Krumeich S; Wen SW; Wiegmans AP; Möller A
Front Immunol; 2018; 9():871. PubMed ID: 29867925
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.
Ling HY; Yang Z; Wang PJ; Sun Y; Ju SG; Li J; Fu JX
Chem Biol Interact; 2022 Jan; 352():109779. PubMed ID: 34922904
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
10. Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway.
Kuang Y; Guo W; Ling J; Xu D; Liao Y; Zhao H; Du X; Wang H; Xu M; Song H; Wang T; Jing B; Li K; Hu M; Wu W; Deng J; Wang Q
Cell Death Dis; 2019 Apr; 10(4):297. PubMed ID: 30931929
[TBL] [Abstract][Full Text] [Related]
11. Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.
Sun S; Wang R; Song J; Guan M; Li N; Zhang X; Zhao Z; Zhang J
J Lipid Res; 2017 Nov; 58(11):2102-2113. PubMed ID: 28874440
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
13. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
Li X; He S; Tian Y; Weiss RM; Martin DT
Cell Signal; 2019 Nov; 63():109381. PubMed ID: 31374291
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
[TBL] [Abstract][Full Text] [Related]
16. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
17. Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.
Kadariya Y; Sementino E; Shrestha U; Gorman G; White JM; Ross EA; Clapper ML; Neamati N; Miller MS; Testa JR
Carcinogenesis; 2022 Dec; 43(12):1137-1148. PubMed ID: 36355620
[TBL] [Abstract][Full Text] [Related]
18. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
[TBL] [Abstract][Full Text] [Related]
19. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
20. Trypanosoma cruzi, the causative agent of Chagas disease, modulates interleukin-6-induced STAT3 phosphorylation via gp130 cleavage in different host cells.
Ponce NE; Carrera-Silva EA; Pellegrini AV; Cazorla SI; Malchiodi EL; Lima AP; Gea S; Aoki MP
Biochim Biophys Acta; 2013 Mar; 1832(3):485-94. PubMed ID: 23253440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
